A new survey report from the International Foundation of Employee Benefit Plans reveals results from a group of Canadian employers regarding considerations and coverage for glucagon-like peptide-1 (GLP-1) drugs, which have historically been used to treat diabetes and are increasingly being used to treat obesity
Endocrinology 1978;103:6105.ArticlePubMed 24
However, there are still more details that require further research and enrichment, such as the interaction of Wnt-BMP , Noggin-Shh , Wnt-Notch , and so on
PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after your first month) to identify how your FTO rs9939609, GLP1R rs6923761, GIPR rs1800437, and MC4R rs17782313 variants influence appetite regulation and weight loss potential
The meds worked perfectly
Semaglutide is a long-term weight solution with substantial benefits when used consistently